Insulin-like Growth Factor-binding Protein 1 (IGFBP-1) (Endocrine Sciences)
Also known as: IGF-binding Protein 1, IGFBP-1
Use
Identify women who are at high risk for developing preëclampsia
Special Instructions
Serum levels of IGFBP-1 exhibit considerable diurnal variation, with levels highest early in the morning and lowest in the evening. Serum IGFBP-1 levels are controlled by insulin, with postprandial insulin increasing significantly, leading to a four- to fivefold decrease in IGFBP-1 levels compared to fasting levels. It is essential to freeze serum samples immediately after collection and maintain them frozen until testing to ensure validity of the test results.
Limitations
Patients with growth hormone deficiency tend to have elevated IGFBP-1 levels, while those with type 2 diabetes, acromegaly, Cushing disease, and polycystic ovary syndrome tend to have low levels. The diurnal variation and rapid decrease in IGFBP-1 postprandial could impact the test's readings. Various physiological conditions such as fasting state and use of certain medications might affect the test results.
Methodology
Immunoassay (ECLIA)
Biomarkers
LOINC Codes
- 12722-5
Result Turnaround Time
6-12 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.1 mL
Container
Red-top tube or gel-barrier tube
Collection Instructions
Transfer the serum into a Labcorp PP transpak frozen purple tube with screw cap (Labcorp No. 49482). Freeze immediately and maintain frozen until tested. Submit separate frozen specimens for each test if multiple tests are ordered.
Storage Instructions
Freeze.
Causes for Rejection
Plasma specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 1 day |
| Refrigerated | 2 days |
| Frozen | 16 months |